Browse DHRS9

Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Microsome membrane Endoplasmic reticulum membrane Note=Associated with microsomal membranes.
Domain PF00106 short chain dehydrogenase
Function

3-alpha-hydroxysteroid dehydrogenase that converts 3-alpha-tetrahydroprogesterone (allopregnanolone) to dihydroxyprogesterone and 3-alpha-androstanediol to dihydroxyprogesterone. May play a role in the biosynthesis of retinoic acid from retinaldehyde, but seems to have low activity with retinoids. Can utilize both NADH and NADPH.

> Gene Ontology
 
Biological Process GO:0001523 retinoid metabolic process
GO:0002138 retinoic acid biosynthetic process
GO:0006066 alcohol metabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0008202 steroid metabolic process
GO:0008207 C21-steroid hormone metabolic process
GO:0008209 androgen metabolic process
GO:0008299 isoprenoid biosynthetic process
GO:0010817 regulation of hormone levels
GO:0016053 organic acid biosynthetic process
GO:0016101 diterpenoid metabolic process
GO:0016102 diterpenoid biosynthetic process
GO:0016114 terpenoid biosynthetic process
GO:0034308 primary alcohol metabolic process
GO:0034754 cellular hormone metabolic process
GO:0042180 cellular ketone metabolic process
GO:0042445 hormone metabolic process
GO:0042448 progesterone metabolic process
GO:0042572 retinol metabolic process
GO:0042573 retinoic acid metabolic process
GO:0042904 9-cis-retinoic acid biosynthetic process
GO:0042905 9-cis-retinoic acid metabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
Molecular Function GO:0004022 alcohol dehydrogenase (NAD) activity
GO:0004745 retinol dehydrogenase activity
GO:0016229 steroid dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0016853 isomerase activity
GO:0016854 racemase and epimerase activity
GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0047035 testosterone dehydrogenase (NAD+) activity
Cellular Component GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
> KEGG and Reactome Pathway
 
KEGG hsa00830 Retinol metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-5365859: RA biosynthesis pathway
R-HSA-162582: Signal Transduction
R-HSA-5362517: Signaling by Retinoic Acid
R-HSA-2453902: The canonical retinoid cycle in rods (twilight vision)
R-HSA-2187338: Visual phototransduction
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DHRS9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DHRS9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DHRS9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3290.532
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5960.54
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1450.845
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9990.0484
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.4230.225
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4690.726
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2210.706
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5620.55
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.2050.264
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1660.199
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4170.291
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4090.151
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DHRS9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DHRS9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DHRS9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DHRS9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DHRS9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DHRS9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DHRS9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDHRS9
Namedehydrogenase/reductase (SDR family) member 9
Aliases RDHL; 3alpha-HSD; RETSDR8; RDH15; SDR9C4; NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxyste ......
Chromosomal Location2q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DHRS9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.